| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | GeneticVariation | BEFREE | Trametinib, a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor, has demonstrated great promise in treating metastatic melanoma associated with BRAF V600E and V600K mutations; however, it also is highly associated with cutaneous adverse events (AEs). | 30489553 | 2018 |
||||
|
0.090 | GeneticVariation | BEFREE | To review and summarize data on cobimetinib, which was approved by the US Food and Drug Administration (FDA) in November 2015 for use in combination with vemurafenib for unresectable or metastatic melanoma with a BRAFV600E or V600K mutation. | 27701080 | 2017 |
||||
|
0.090 | GeneticVariation | BEFREE | BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma. | 28738051 | 2017 |
||||
|
0.090 | GeneticVariation | BEFREE | In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone. | 26433819 | 2015 |
||||
|
0.090 | GeneticVariation | BEFREE | We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-positive unresectable stage IIIC or stage IV melanoma. | 26037941 | 2015 |
||||
|
0.090 | GeneticVariation | BEFREE | BRAF inhibitor activity in V600R metastatic melanoma. | 23237741 | 2013 |
||||
|
0.090 | GeneticVariation | BEFREE | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. | 23051966 | 2012 |
||||
|
0.090 | GeneticVariation | BEFREE | The aim of the present study was to investigate the frequency of the less common p.Val600Lys (V600K) mutation in metastatic melanoma from a high incidence region. | 22614711 | 2012 |
||||
|
0.090 | GeneticVariation | BEFREE | Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. | 22535154 | 2012 |